WASHINGTON, Sept. 16 (Xinhua) -- Participants of a phase 3 clinical trial of American biopharmaceutical company Pfizer's COVID-19 vaccine candidate were experiencing mild-to-moderate side effects, said the company on Tuesday.
In a presentation to investors, Pfizer said side effects included fatigue, headache, chills and muscle pain. Some participants in the trial also developed fevers, including a few high fevers.
Already a subscriber? Log in.
Celebrate Merdeka with 50% Off!
T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
